NASDAQ:ZEAL Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free ZEAL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$17.59▼$17.5950-Day Range$16.54▼$19.2052-Week Range$9.93▼$32.94VolumeN/AAverage Volume4,965 shsMarket Capitalization$818.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zealand Pharma A/S alerts: Email Address Ad Augury ResearchBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is currently auctioning off CITGO (the winning bid will be announced on July 22nd).Get all the details here. About Zealand Pharma A/S Stock (NASDAQ:ZEAL)Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Read More Ad Augury ResearchBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is currently auctioning off CITGO (the winning bid will be announced on July 22nd).Get all the details here. ZEAL Stock News HeadlinesJune 7 at 4:38 AM | globenewswire.comZealand Pharma announces that Boehringer Ingelheim's survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosisJune 6 at 6:29 AM | globenewswire.comZealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASLJune 6 at 6:29 AM | globenewswire.comZealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASLMay 31, 2024 | globenewswire.comZealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines AgencyMay 29, 2024 | globenewswire.comZealand Pharma to participate in upcoming healthcare investor conferences in June 2024May 29, 2024 | globenewswire.comZealand Pharma major shareholder announcement: Polar CapitalMay 28, 2024 | morningstar.comZealand Pharma A/S ZLDPFMay 28, 2024 | msn.comDavid Seymour’s special envoy in medicines is dumping his drug company investmentsMay 23, 2024 | globenewswire.comZealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutideMay 16, 2024 | nasdaq.comZealand Pharma Q1 Loss Widens - Quick FactsMay 16, 2024 | globenewswire.comZealand Pharma Announces Financial Results for the First Quarter of 2024May 12, 2024 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsMay 9, 2024 | globenewswire.comZealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial resultsApril 28, 2024 | msn.comAct’s arts spokesman once watched a musicalApril 28, 2024 | msn.comBig Pharma’s dogfight to dominate the anti-obesity marketApril 23, 2024 | tmcnet.comZealand Pharma Partners with Benchling to Advance R&D of Engineered Peptide MedicinesApril 19, 2024 | globenewswire.comCorrection to Company announcement – No. 23 / 2024April 19, 2024 | finance.yahoo.comZealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024April 19, 2024 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsApril 19, 2024 | globenewswire.comZealand Pharma launches long-term incentive programs for Zealand's Board of Directors, Corporate Management and employees for 2024April 19, 2024 | msn.comMarkets with Madison: NZ medicinal cannabis company Cannasouth’s ex-chief executive Mark Lucas talks about what went wrongApril 19, 2024 | msn.comPharmac's perpetually stretched budgetApril 19, 2024 | msn.comNew Zealand Jobs: What is changing for new applicants of Accredited Employer Work VisaApril 19, 2024 | msn.comDrugs Like Ozempic And Mounjaro Could Treat Other Conditions—Here’s What Scientists Are Looking AtApril 12, 2024 | ft.comA ghost of Brexit past returns to haunt LabourSee More Headlines Receive ZEAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today6/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZEAL CUSIPN/A CIK1674988 Webwww.zealandpharma.com Phone(458) 877-3600Fax45-8877-3898Employees355Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,990,000.00 Net Margins-565.44% Pretax Margin-364.34% Return on Equity-111.04% Return on Assets-56.54% Debt Debt-to-Equity Ratio0.93 Current Ratio4.79 Quick Ratio4.78 Sales & Book Value Annual Sales$46.54 million Price / Sales17.59 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book5.20Miscellaneous Outstanding Shares46,538,000Free Float45,514,000Market Cap$818.60 million OptionableNot Optionable Beta1.45 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Adam Sinding Steensberg M.D. (Age 48)Pres & CEO Comp: $680.16kMr. Ivan Mourits Moller (Age 50)Chief Operating Officer Lani Pollworth MorvanInvestor Relations & Communications OfficerMr. Mads KronborgHead of Investor Relations & CommunicationMr. Ravinder ChahilSr. VP & Gen. CounselMs. Christina Sonnenborg Bredal (Age 37)Sr. VP and Global Head of People & Organization Ms. Hanne Heidenheim Bak (Age 69)Sr. Project Director, R&D Operations Mang. and Employee Representative Director Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular PharmacologyDr. Danilo VergeHead of Global Medical AffairsDr. David M. Kendall M.D. (Age 60)Chief Medical Officer More ExecutivesKey CompetitorsPrestige Consumer HealthcareNYSE:PBHArrowhead PharmaceuticalsNASDAQ:ARWRAmicus TherapeuticsNASDAQ:FOLDMerusNASDAQ:MRUSBiohavenNYSE:BHVNView All Competitors ZEAL Stock Analysis - Frequently Asked Questions Should I buy or sell Zealand Pharma A/S stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZEAL shares. View ZEAL analyst ratings or view top-rated stocks. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (NASDAQ:ZEAL) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($4.61) earnings per share for the quarter, topping the consensus estimate of ($6.31) by $1.70. The business had revenue of $16.87 million for the quarter, compared to the consensus estimate of $12.21 million. Zealand Pharma A/S had a negative net margin of 565.44% and a negative trailing twelve-month return on equity of 111.04%. During the same period in the prior year, the company posted ($0.90) earnings per share. What other stocks do shareholders of Zealand Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE). When did Zealand Pharma A/S IPO? Zealand Pharma A/S (ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. This page (NASDAQ:ZEAL) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Zealand Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.